Alerta

Amanita Muscaria Mushroom Extracts and Products, and Improved Processes for Producing Extracts of Amanita Muscaria Mushrooms at Kilogram Scale

Resumen de: US20260256858A1

0000 Disclosed herein are processes for extracting muscimol from Amanita mushrooms, and more particularly, from Amanita muscaria, including processes that increase muscimol content and decrease ibotenic acid content, and further including improved processes that produce extract at scale, such as at kilogram scale. In some aspects are methods for selecting Amanita mushroom biomass suitable for the disclosed extraction methods, so as to produce extracts and products that are safe and beneficial for human use. Also disclosed are numerous compositions and formulations made with disclosed extracts, including beverage formulations, having a variety of improvements and advantages over previously known products made from Amanita muscaria.

血浆中脂磷壁酸（LTA）和/或脂多糖（LPS）阳性细胞外囊泡的用途

Resumen de: CN122651547A

本发明属于医药健康领域，涉及血浆中脂磷壁酸(LTA)和/或脂多糖(LPS)阳性细胞外囊泡在细菌性炎症和/或菌血症的检测中的用途。具体地，本发明提供了一种细菌性炎症和/或菌血症的体外检测方法，包含以下步骤：提供来自受试对象的待测样本；从所述待测样本中分离细胞外囊泡；检测LPS阳性的细胞外囊泡(LPS+EVs)的水平，和/或LTA阳性的细胞外囊泡(LTA+EVs)的水平；如果LPS+EVs和/或LTA+EVs水平增加，则指示所述受试对象存在细菌性炎症和/或菌血症。

一种生物探针、检测大肠杆菌O157：H7的试纸条及应用

Resumen de: CN122652024A

0001 本发明公开了一种生物探针、检测大肠杆菌O157：H7（ Escherichia coli O157:H7 ）的试纸条及应用。以超声辅助金属离子合成金基纳米合金，采用贻贝化学策略在合金基础上包覆聚多巴胺涂层，最终以AuMnCu@PDA作为信号示踪剂，利用天然贻贝富集的黑色条带和多原子调谐增强的等离子基元，不仅增强了传统的第一比色强度，而且引入了第二光热信号，大大增强了检测灵敏度。比色和光热信号下灵敏度较传统纳米金分别提高了100倍和1000倍，同时具有优异的稳定性和分散性，更有利于构建灵敏、准确的双峰型ICA。这项工作通过简便且绿色的贻贝化学策略为免疫层析测定的信号增强和性能改进开辟了新的途径，为提高分析性能和扩大ICA的实际应用提供了广阔的前景。

K64型肺炎克雷伯菌荚膜多糖单克隆抗体、其杂交瘤细胞株及其应用

Resumen de: CN118620072A

The invention discloses a klebsiella pneumoniae polysaccharide monoclonal antibody, a hybridoma cell strain and application of the klebsiella pneumoniae polysaccharide monoclonal antibody, the sequence information of the klebsiella pneumoniae polysaccharide monoclonal antibody is shown as SEQ NO: 1-SEQ NO: 64, and the preservation numbers of the hybridoma cell strain are respectively CCTCC: C2023296, CCTCC: C2023311, CCTCC: C2023312, CCTCC: C2023313, CCTCC: C2023314, CCTCC: C2023365, CCTCC: C2023366 and CCTCC: C2023367. The klebsiella pneumoniae polysaccharide monoclonal antibody provided by the invention can be specifically combined with capsular polysaccharide of klebsiella pneumoniae, is beneficial to typing of the klebsiella pneumoniae in clinic, and can prove that the klebsiella pneumoniae polysaccharide monoclonal antibody has an excellent effect of preventing and treating K47 type and K64 type klebsiella pneumoniae infection through in-vivo and in-vitro tests of animals; the invention provides a way for solving the problems of klebsiella pneumoniae infection and multiple drug resistance, has obvious significance for preventing, diagnosing and treating klebsiella pneumoniae infection, and has important value for developing a new generation of klebsiella pneumoniae medicine.

BACTERIOPHAGE, SALMONELLA BACTERIOLYTIC AGENT, COMPOSITION, AND METHOD FOR CONTROLLING BACTERIA OF THE GENUS SALMONELLA

Resumen de: US20260248139A1

A novel bacteriophage having bacteriolytic activity against bacteria of the genus Salmonella, such as S. Enteritidis, and a bacteriolytic agent consisting of the same are provided. The bacteriophage and the bacteriolytic agent including the bacteriophage have a wide host range for bacteria of the genus Salmonella. A host-specific bacteriophage and an effective Salmonella bacteriolytic agent consisting of the same are provided. A bacteriophage capable of effectively controlling S. Typhimurium, and in particular, multidrug-resistant S. Typhimurium, and a bacteriolytic agent consisting of the same are also provided. A bacteriophage having a specific genomic DNA sequence; a Salmonella bacteriolytic agent consisting of the bacteriophage; and a composition comprising the same are provided.

BACTERIOPHAGES, LYTIC AGENTS FOR SALMONELLA SPECIES, COMPOSITIONS, AND METHOD FOR CONTROLLING SALMONELLA SPECIES

Resumen de: US20260248866A1

0000 An object of the present disclosure is to provide (i) a novel bacteriophage having lytic activity against a Salmonella species such as S. enteritidis or a lytic agent including the same, (ii) a bacteriophage having a broad host range against Salmonella species or a lytic agent including the same, (iii) a host-specific bacteriophage or an effective lytic agent for a Salmonella species including the same, or (iv) a bacteriophage or a lytic agent including the same, capable of effectively controlling S. typhimurium, particularly S. typhimurium having multidrug resistance. The present disclosure provides bacteriophages having specific genomic DNA sequences, lytic agents for Salmonella species including the same, and compositions including the same.

BACTERIOPHAGE, COMPOSITION, AND METHOD FOR CONTROLLING BACTERIA OF THE GENUS SALMONELLA

Resumen de: US20260248865A1

0000 A bacteriophage having a wide host range for bacteria of the genus Salmonella is provided. The bacteriophage has bacteriolytic activity against bacteria of the genus Salmonella. The bacteriophage has a genomic DNA sequence comprising a gene encoding a tail tip protein consisting of a specific amino acid sequence. Methods of using the bacteriophage are also provided.

与大肠杆菌特异结合的适配体、生物传感器、试剂盒及用途

Resumen de: CN122629066A

本发明公开了与大肠杆菌特异结合的适配体、生物传感器、试剂盒及用途，属于生物技术与体外诊断技术领域。该适配体包括如SEQ ID NO.1所示的核心序列；其中含有如SEQ ID NO.3所示的核心结合基序，完整序列如SEQ ID NO.2所示。本发明基于活体全菌SELEX技术筛选的适配体对大肠杆菌的亲和力高，特异性强，对复杂样本中的大肠杆菌的捕获效率显著提升。

早产儿视网膜病变的肠道菌群标志物组合及其应用

Resumen de: CN122629198A

0001 本发明适用于生物医学诊断技术领域，提供了一种早产儿视网膜病变的肠道菌群标志物组合及其应用，其中，该肠道菌群标志物组合包括产气克雷伯菌和/或丁酸梭菌作为检测靶标。本发明首次在种水平上鉴定出与早产儿视网膜病变风险相关的特异性肠道菌群标志物；其中，肠道菌群中的产气克雷伯菌的丰度与早产儿视网膜病变的风险呈正相关，可作为早产儿视网膜病变的风险预警标志物；肠道菌群中的丁酸梭菌的丰度与早产儿视网膜病变的风险呈负相关，可作为早产儿视网膜病变的保护性标志物；本发明为早产儿视网膜病变的早期预警、风险评估及预后判断提供了全新的无创检测靶点。

一种胸苷依赖型的鼠伤寒沙门氏菌工程菌及其组合物与应用

Resumen de: CN122609470A

本发明属于生物医药领域，具体涉及一种胸苷依赖型的鼠伤寒沙门氏菌工程菌及其组合物与应用。所述工程菌以鼠伤寒沙门氏菌VNP20009为出发菌株，经敲除胸苷酸合成酶基因thyA和插入腺苷脱氨酶编码基因，获得生长依赖外源嘧啶核苷酸、胞内表达或外膜表达腺苷脱氨酶的工程菌；胞内表达腺苷脱氨酶的工程菌为鼠伤寒沙门氏菌VNP20009‑cADD，保藏号为CGMCC No.37959；外膜表达腺苷脱氨酶的工程菌为鼠伤寒沙门氏菌VNP20009‑wADD，保藏号为CGMCC No.37956。该工程菌可肿瘤靶向定植、安全性更高，能在肿瘤局部降解腺苷、解除免疫抑制，联合放疗或免疫检查点抑制剂时可显著抑制实体瘤生长。

一种检测沙门氏菌的SERS探针及试剂盒和检测方法

Resumen de: CN122612924A

0001 本发明属于致病菌检测技术领域，具体涉及一种检测沙门氏菌的SERS探针及试剂盒和检测方法。该SERS探针由金纳米双锥内核、包被金纳米双锥的普鲁士蓝壳层和偶联于探针表面的鼠伤寒沙门氏菌单克隆抗体组成，可结合噬菌体修饰的氨基化磁珠捕获技术，用于鼠伤寒沙门氏菌检测，在785 nm激发下，采集2151 cm<‑1>附近的SERS信号。结果表明，本发明的探针及检测方法，对鼠伤寒沙门氏菌的检测限为1 CFU/mL，具有良好的特异性，可避免背景干扰及其他病原菌干扰。

C-反应蛋白功能化广谱病原体捕获磁珠的制备及其在细菌-病毒共感染免疫层析检测中的应用

Resumen de: CN122612907A

0001 本发明公开一种C‑反应蛋白功能化广谱病原体捕获磁珠的制备及其在细菌‑病毒共感染免疫层析检测中的应用，基于CRP的复合标记物（CRP‑MDQD）通过逐层自组装策略在Fe<3>O<4>表面连续包覆两层致密的CdSe/ZnS‑COOH量子点构建而成，并公开了其在LFIA中同步富集检测铜绿假单胞菌和SARS‑CoV‑2 NP的应用价值。CRP‑MDQD LFIA平台实现了铜绿假单胞菌与SARS‑CoV‑2 NP的无抗体同步富集检测。该生物传感器具有卓越的基质耐受性，其"抗体非依赖"设计突破了传统多重检测的固有局限，为资源有限环境下病毒‑细菌混合感染的快速分诊提供了变革性床旁解决方案。

一种集成微流控的小型化电化学生物传感器芯片及其制备方法

Resumen de: CN122612721A

0001 本发明涉及生物传感与微流控领域，具体公开了一种集成微流控的小型化电化学生物传感器芯片及其制备方法，包括微流控芯片主体和集成于其内的电化学生物传感器，微流控芯片主体内部设有微流控通道结构，电化学生物传感器包括基底及设置于基底上的工作电极、对电极和参比电极，微流控通道结构与工作电极的表面流体连通。本发明通过将微流控通道与三电极体系在微小面积内一体化集成，并对芯片的整体尺寸、基底厚度及重量进行协同优化，在保证流体密封与键合强度的前提下实现了芯片的显著小型化和轻量化，使其能够灵活适配无人平台载荷，满足移动化、现场化的快速生物侦检需求。

Compositions and methods for detecting gastrointestinal pathogens

Resumen de: AU2026208127A1

Compositions, methods, kits, and uses are provided for detecting the presence of Salmonella, Shigella, Campylobacter, and Shigatoxigenic Escherichia coli (STEC) in samples. In some embodiments, the compositions, methods, kits, and uses comprise one or more oligonucleotides or the use of one or more oligonucleotides. ul u l

ANTIMICROBIAL PEPTIDES

Resumen de: US20260242416A1

Antimicrobial peptides (AMPs) exhibiting broad spectrum antimicrobial activity are described. Such peptides are useful in treating or preventing infections and other conditions, and are of special interest for treating antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach leading to identification of numerous antimicrobial peptides from known genomic sequences is described.

ORAL VACCINE

Resumen de: US20260240985A1

0000 The present invention relates to a non-viable bacterium cell wherein an immunogenic polypeptide fused to an auto-transporter comprising transmembrane linker and a trans-porter domain is displayed on the surface of the cell, and to a preparation comprising such non-viable cells. The preparation is useful as an oral vaccine.

CONTRACTILE INJECTION SYSTEM AND USE THEREOF

Resumen de: US20260242806A1

0000 The invention relates to re-engineering of a natural microbial syringe for loading of effector proteins that are not naturally found as cargo of the specific syringe. The cargo, that is one or more effector protein and proteins required for packing, can be up to 300 kDa and can be proteins such as toxins, therapeutic proteins, and gene modification tools. The re-engineering of the natural syringe result in a contractile injection system that allows packing of large cargo and cargo combinations, such as toxin-chimeras. The system comprises a Conserved Virulence Cassette encoding the syringe structure and is co-expressed with a sequence encoding cargo and a signal peptide. The signal peptide comprises a packing motif that enables packing of cargo into the syringe. The contractile injection system can be used for agricultural purposes as well as for medicinal purposes.

BIOSENSORS AND RELATED METHODS

Resumen de: US20260243764A1

Described herein is a biosensor for detecting the presence of a target molecule in a sample. The biosensor comprises: a polymeric hydrogel; a colorimetric indicator entrapped in the polymeric hydrogel; and an oligonucleotide that crosslinks the polymeric hydrogel, wherein the oligonucleotide is separated in the presence of the target molecule, thereby releasing the colorimetric indicator from the hydrogel.

プログラムされた死のリガンド－１（ＰＤ－ＬＩ）発現の画像化および標的化

Resumen de: WO2022032100A2

The presently disclosed subject matter provides compositions, kits, and methods comprising imaging agents that can detect Programmed Cell Death Ligand 1 (PD-L1). The presently disclosed imaging agents can be used to detect diseases and disorders, such as cancer, infection, and inflammation, in a subject.

VACCINE COMPOSITIONS COMPRISING SIALIC ACID BINDING DOMAIN (SBD) PROTEINS AND USE THEREOF TO ENHANCE IMMUNE RESPONSE

Resumen de: WO2025080776A2

Aspects of the invention described herein relate to a vaccine composition comprising at an antigenic polysaccharide and an immunomodulatory amount of a sialic acid binding moiety, wherein the sialic acid binding moiety comprises sialic acid binding domain (SBD) which is not fused to an antigenic polypeptide.

一种兼具光热灭菌功能的适配体介导比率型光电化学传感器的构建方法和应用

Resumen de: CN122591946A

0001 本发明公开了一种兼具光热灭菌功能的适配体介导比率型光电化学传感器的构建方法和应用，涉及光电化学检测技术领域。本发明融合原位光热灭菌与信号放大技术，利用光热作用使捕获菌体裂解释放脂多糖，通过脂多糖与传感界面的特异性相互作用增强光电流响应，实现高效信号放大，完成目标菌精准定量检测。本发明实现灭菌与检测一体化，构建安全传感检测体系，从源头杜绝活菌外泄引发的感染隐患，保障操作生物安全，方法实用性强、抗干扰能力优，可高效完成样本中待测菌快速精准检测，适用范围广。

一种检测血流感染病原体的试剂盒

Resumen de: CN122591955A

0001 本发明提供了一种检测血流感染病原体的试剂盒，属于免疫检测技术领域。本发明所述试剂盒包括优化后的样品处理液和包被液，所述样品处理液以PBS缓冲液为基底，包含Triton X‑100、皂苷、聚乙二醇6000、PC300、EDTA‑Na<2>、BSA和柠檬酸钠；所述包被液以碳酸盐缓冲液为基底，包含海藻糖、SDS、甲醇、BSA、PC300和脯氨酸。本发明提供的试剂盒可以实现血流感染病原体高灵敏度、高特异性、快速检测，且储存稳定、适用范围广、兼容性强，适用于临床血流感染中常见细菌、真菌等病原体的快速检测。

一种基于细菌的肿瘤原位疫苗及其制备方法和应用

Resumen de: CN122582271A

本发明公开一种基于细菌的肿瘤原位疫苗，包括灭活细菌和腺苷脱氨酶，所述灭活细菌为大肠杆菌(Escherichia coli) Nissle 1917或减毒鼠伤寒沙门氏菌(VNP 20009)中的任意一种或两种。本发明的肿瘤原位疫苗对宿主脏器无明显毒副作用，具有良好的安全性，生产制备工艺简单、成本低；可通过瘤内注射方式刺激机体先天性和适应性免疫系统，增强抗肿瘤免疫，抑制肿瘤细胞生长，有效预防肿瘤的发生发展和复发转移。

TolC CK139 A novel Salmonella enterica typhimurium CK139 strain lacking the TolC gene and its use

Resumen de: KR20260124251A

본 발명은 TolC 유전자가 결손된 신규 살모넬라 엔테리카 타이피뮤리움(Salmonella enterica Typhimurium) CK139 균주 및 상기 균주가 분비하는 단백질에 관한 것으로, 살모넬라 엔테리카 타이피뮤리움(Salmonella enterica Typhimurium) 균주에서 외막 단백질인 TolC에 대한 유전자가 결손된 돌연변이 균주인 살모넬라 엔테리카 타이피뮤리움(Salmonella enterica Typhimurium) CK139 균주가 철 이온의 농도에 따라 분비 단백질의 패턴이 유의적으로 변화되는 것을 확인하고, 낮은 철 이온 농도에서 에코틴(ecotin) 단백질의 분비가 유의적으로 증가되는 것을 확인하였으며, 상기 CK139 균주 또는 에코틴(ecotin) 단백질을 마우스에 주사한 결과 염증성 장질환이 악화됨을 확인함에 따라 상기 CK139 균주 또는 에코틴(ecotin) 단백질을 염증성 장질환의 악화 인자를 확인하고, 이를 이용하여 염증성 장질환 동물 모델의 제조 방법을 제공한다.

サルモネラに基づく新規コロナウイルスワクチン

Nº publicación: JP2026131609A 14/08/2026

Solicitante:

エンエーセーオンコイミュニティアクスイェセルスカプ

Resumen de: CN115715198A

The present invention relates to a DNA vaccine comprising a Salmonella typhi Ty21a strain, the Salmonella typhi Ty21a strain comprising a DNA molecule, the DNA molecule comprising an eukaryotic expression cassette encoding at least a COVID-19 coronavirus (SARS-CoV-2) spike (S) protein or a portion thereof. In particular, the invention relates to the application of the DNA vaccine to prevention and/or treatment of the coronavirus disease COVID-19 or SARS-CoV-2 infection.